|
Summary Information: Catalyst Biosciences Inc. Common Stock NASDAQ:CBIO |
  admin@troach.net |
Our Main Pages Stocks.TRoach.Net TRoach.Org TRoach.Net |
_Description: Catalyst is a research and clinical development biopharmaceutical company focused on addressing unmet medical needs in rare disorders of the complement and coagulation systems. Its protease engineering platform has generated two late-stage clinical programs, including MarzAA, a subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with rare bleeding disorders. Its complement pipeline includes a pre-clinical C3-degrader program partnered with Biogen for dry age-related macular degeneration, an improved complement factor I protease for SQ replacement therapy in patients with CFI deficiency and C4b-degraders designed to target disorders of the classical complement pathway as well as other complement programs in development.
__The following are links to various summary and news pages for __Catalyst Biosciences Inc. Common Stock [ CBIO ]. __Note: Some Links might not have information for the company. |
|